Purple Biotech (PPBT) 20-F 5 Mar 18 2017 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2017shares
Document and Entity Information [Abstract]
Entity Registrant Name	Kitov Pharma Ltd.
Entity Central Index Key	1,614,744
Amendment Flag	false
Trading Symbol	KTOV
Current Fiscal Year End Date	--12-31
Document Type	20-F
Document Period End Date	Dec. 31, 2017
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	0

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	$ 3,947	$ 6,758
Short term deposits	3,488	7,899
Other current assets	548	241
Total current assets	7,983	14,898
Fixed assets, net	28	16
Intangible assets	6,172
Total assets	14,183	14,914
Liabilities
Accounts payable	215	515
Other payables	1,841	758
Derivative instruments	2,012
Total current liabilities	4,068	1,273
Non-current liabilities
Derivative instruments	1,030
Post-employment benefit liabilities	492	256
Total non - current liabilities	1,522	256
Equity
Share capital, no par value
Share premium	35,979	30,826
Receipts on account of warrants	7,415	7,415
Capital reserve for share-based payments	1,725	583
Capital reserve from transactions with related parties	761	761
Accumulated loss	(38,567)	(26,200)
Equity attributable to owners of the Company	7,313	13,385
Non-controlling interests	1,280
Total equity	8,593	13,385
Total liabilities and equity	$ 14,183	$ 14,914

Consolidated Statements of Oper

Consolidated Statements of Operations and Other Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Profit or loss [abstract]
Research and development expenses	$ 4,640	$ 4,180	$ 2,560
General and administrative expenses	6,392	3,003	1,509
Other expenses	1,029
Operating Loss	12,061	7,183	4,069
Net change in fair value of derivatives	1,049	5,019	(94)
Finance expense	26	61	227
Finance income	(128)	(138)	0
Finance expenses, net	947	4,942	133
Loss for the year	13,008	12,125	4,202
Other comprehensive loss Items that will not be classified to profit or loss
Re-measurement of defined benefit liability	95	21
Total comprehensive loss for the year	13,103	12,146	4,202
Loss attributable to:
Owners of the Company	12,272	12,125	4,202
Non-controlling interests	736
Total Loss attributable	13,008	12,125	4,202
Total comprehensive loss attributable to:
Owners of the Company	12,367	12,146	4,202
Non-controlling interests	736
Total comprehensive loss for the year	$ 13,103	$ 12,146	$ 4,202
Loss per share data
Basic and diluted loss per share - USD	$ 0.07	$ 0.11	$ 0.22
Number of shares used in calculating basic and diluted loss per share	189,139,031	115,114,946	19,250,340

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Share Capital	Share premium	Receipts on account of warrants	Capital reserve for share-based payments	Capital reserve from transactions with related parties	Accumulated loss	Total equity	Non-controlling interests
Balance at Dec. 31, 2014	$ 773		$ 9,104	$ 200	$ 560	$ 761	$ (9,852)
Transactions with owners of the company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs	10,531		10,531
Issuance of shares, net of issuance costs	1,821		1,821
Issuance of warrants, net of issuance costs	27			27
Share issuance due to a strategic cooperation agreement	417		500		(83)
Share-based payments	59				59
Exercise and expiration of warrants (series 1)	1		201	(200)
Exercise of warrants (series 2)	2		2
Comprehensive loss for the year:
Loss for the year	(4,202)						(4,202)
Total comprehensive loss for the year	(4,202)
Balance at Dec. 31, 2015	9,429		22,159	27	536	761	(14,054)
Transactions with owners of the company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs	5,222		5,222
Issuance of warrants, net of issuance costs	2,517			2,517
Share issuance due to a strategic cooperation agreement	250		500		(250)
Share-based payments	400		103		297
Transfer of derivative instrument from liability to equity	7,388			7,388
Exercise of warrants (series A)	302		302
Exercise of warrants (series B)	23		2,540	(2,517)
Total transactions with owners of the company	16,102		8,667	7,388	47
Comprehensive loss for the year:
Loss for the year	(12,125)						(12,125)
Other comprehensive loss	(21)						(21)
Total comprehensive loss for the year	(12,146)						(12,146)
Balance at Dec. 31, 2016	13,385		30,826	7,415	583	761	(26,200)	$ 13,385
Transactions with owners of the company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs	2,174		2,174					2,174
Share issuance due to an acquisition of a subsidiary (see note 4)	3,816		1,800					1,800	2,016
Share-based payments	2,321		96		2,225			2,321
Issuance of shares due to RSUs vesting			1,083		(1,083)
Total transactions with owners of the company	8,311		5,153		1,142			6,295	2,016
Comprehensive loss for the year:
Loss for the year	(13,008)						(12,272)	(12,272)	(736)
Other comprehensive loss	95						(95)	(95)
Total comprehensive loss for the year	(13,103)						(12,367)	(12,367)	(736)
Balance at Dec. 31, 2017	$ 8,593		$ 35,979	$ 7,415	$ 1,725	$ 761	$ (38,567)	$ 7,313	$ 1,280

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Loss for the year	$ (13,008)	$ (12,125)	$ (4,202)
Adjustments:
Depreciation	4	2	1
Finance expense, net	947	4,942	133
Share-based payments	2,308	400	59
Expenses in regards with settlement with a minority shareholder of a subsidiary (see note 12)	1,000
Expenses in regard to a strategic cooperation agreement		250	417
Total adjustments	(8,749)	(6,531)	(3,592)
Changes in assets and liabilities:
Changes in other receivables	(273)		197
Changes in accounts payable	(491)	(138)	(152)
Changes in other payables	745	357	54
Changes in post-employment benefit liabilities	141	50	185
Changes in assets and liabilities, total	122	269	284
Net cash used in operating activities	(8,627)	(6,262)	(3,308)
Cash flows from investing activities:
Acquisition of subsidiary (see Note 4)	(1,732)
Decrease (increase) in short term deposits	4,411	(7,899)
Interest received	106	138
Acquisition of fixed assets	(13)	(10)	(9)
Net cash provided by (used in) investing activities	2,772	(7,771)	(9)
Cash flows from financing activities:
Repayment of loans from related parties	(130)		(294)
Short-term credit from bank	(16)
Proceeds from issuance of shares and ADSs	2,419	6,287	14,942
Share and ADS issuance expenses paid	(245)	(1,065)	(2,059)
Proceeds from issuance of warrants	1,107	5,713	190
Warrants issuance expenses paid	(114)	(968)	(10)
Receipts from warrant exercise		325	2
Interest paid	(26)	(6)	(145)
Net cash provided by financing activities:	2,995	10,286	12,632
Net increase (decrease) in cash	(2,860)	(3,747)	9,315
Cash at the beginning of the year	6,758	10,558	1,313
Effect of translation adjustments on cash	49	(53)	(70)
Cash at end of the year	$ 3,947	$ 6,758	$ 10,558

General

General	12 Months Ended
	Dec. 31, 2017
General [Abstract]
General	Note 1 - General Reporting entity Kitov Pharma Ltd. (formerly “Kitov Pharmaceuticals Holdings Ltd.”) (hereinafter: “the Company Kitov “the Acquisition” In January 2018, the Company changed its name to Kitov Pharma Ltd. The Company’s securities (American Depository Shares (“ADS”) as well as Series A warrants) were listed for trading on the NASDAQ in November 2015. Each ADS represents 20 ordinary shares with no par value. Each warrant enables the purchase of 1 ADS. In December 2017, the Company completed its merger with Kitov, with the Company remaining as the surviving entity. The Company received the Merger Certificate from the Israeli Registrar of Companies with a merger date effective as of December 14, 2017. As set forth in the Agreement and Plan of Merger between the Company and Kitov, and in accordance with Section 103 of the Israeli Income Tax Ordinance [New Version], 1961, the merger shall be deemed to have been consummated on, and effective as of, December 31, 2017. The Company’s address is One Azrieli Center, Round Tower, 132 Menachem Begin Road, Tel-Aviv 6701101 Israel. In January 2017, the Company acquired the majority of shares of TyrNovo Ltd. (hereinafter: “ TyrNovo The Company together with Kitov and TyrNovo are referred to, in these financial statements, as “the Group As of the date of the financial statements, the Group is engaged, through Kitov, in the development of combination drugs that treat two clinical conditions simultaneously, pain caused by osteoarthritis and hypertension, and through TyrNovo, in the development of a small molecule that has demonstrated the potential to overcome resistance to multiple anti-cancer drugs . Since incorporation through December 31, 2017, the Group has incurred losses and negative cash flows from operations mainly attributed to its development efforts and has an accumulated deficit of USD 38.6 million. The Group has financed its operations mainly through private and public financing rounds. In November 2015, July 2016, and July 2017, the Group raised a total of USD 23.6 million net. At present, the Group has no revenue and will require additional funding for future plans. Management anticipates that its existing capital resources will be adequate to satisfy liquidity requirements for the next 12 months. Subsequently, management’s plans include pursuing alternative financing arrangements or reducing expenditures as necessary to meet the Company’s future cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity.

Basis of Preparation of the Fin

Basis of Preparation of the Financial Statements	12 Months Ended
	Dec. 31, 2017
Basis of Preparation of the Financial Statements [Abstract]
Basis of Preparation of the Financial Statements	Note 2 - Basis of Preparation of the Financial Statements A. Statement of compliance with International Financial Reporting Standards The Group has prepared the financial statements in accordance with International Financial Reporting Standards (hereinafter: “IFRS”), as issued by the International Accounting Standard Board (“IASB”). These financial statements have been approved by the board of directors on February 27, 2018. B. Functional and presentation currency These financial statements are presented in US dollars (USD), which is the Group’s functional currency, rounded to the nearest one thousand, unless otherwise noted. The USD is the currency that represents the principal economic environment in which the Group operates. C. Use of estimates and judgment The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Management prepares the estimates on the basis of past experience, various facts, external circumstances, and reasonable assumptions according to the pertinent circumstances of each estimate. The preparation of accounting estimates used in the preparation of the Group’s financial statements requires management of the Group to make assumptions regarding circumstances and events that involve considerable uncertainty. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about assumptions made by the Group with respect to the future and other reasons for uncertainty with respect to estimates that have a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in the next financial year are included in Note 12. Fair value measurement The Group’s management regularly reviews significant unobservable inputs and valuation adjustments, including obtaining valuations prepared by third parties and assessing the evidence to support the conclusion that these valuations meet the requirements of IFRS, including the level in the fair value hierarchy in which the valuations should be classified. Significant valuation issues are reported to the Group Audit Committee. When measuring the fair value of an asset or liability, the Group uses market observable data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows: - Level 1: quoted prices in active markets for identical assets or liabilities. - Level 2: inputs other than quoted prices included in Level 1, that are observable for the asset or liability, either directly or indirectly. - Level 3: inputs for the asset or liability that are not based on observable market data. If the inputs used to measure the fair value of an asset or a liability might be categorized in different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement. The Group recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. Further information about the assumptions made in measuring fair value of share based payments and derivative liability are included in Note 10 and Note 20, respectively. D. Exchange rates and linkage bases Balances in foreign currency or linked thereto are included in the financial statements at the representative exchange rates, as published by the Bank of Israel, which were prevailing as of the statement of financial position date. Data on exchange rates are as follows: Representative exchange rate of USD (NIS/USD 1) Date of financial statements: December 31, 2017 3.467 December 31, 2016 3.845 December 31, 2015 3.902 Changes in exchange rates for the Year ended: % December 31, 2017 (9.8 ) December 31, 2016 (1.5 ) December 31, 2015 0.3

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Significant Accounting Policies [Abstract]
Significant Accounting Policies	Note 3 - Significant Accounting Policies The accounting policies set out below have been consistently applied for all periods presented in these consolidated financial statements: A. Basis of consolidation 1. Business combination The Group accounts for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognized in profit or loss immediately. Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities. The consideration transferred does not include amounts related to the settlement of pre-existing relationships. Such amounts are generally recognized in profit or loss. Any contingent consideration is measured at fair value at the date of acquisition. If an obligation to pay contingent consideration that meets the definition of a financial instrument is classified as equity, then it is not re-measured and settlement is accounted for within equity. Otherwise, other contingent consideration is re-measured at fair value at each reporting date and subsequent changes in the fair value of the contingent consideration are recognized in profit or loss. If share-based payment awards (replacement awards) are required to be exchanged for awards held by the acquiree’s employees (acquiree’s awards), then all or a portion of the amount of the acquirer’s replacement awards is included in measuring the consideration transferred in the business combination. This determination is based on the market-based measure of the replacement awards compared with the market-based measure of the acquiree’s awards and the extend to which the replacement awards relate to the pre-combination service. 2. Subsidiary Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. 3. Non-controlling interests Non-controlling interests are measured initially at their proportionate share of the acquiree’s identifiable net assets at the date of acquisition. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. B. Foreign currency transactions Transactions in foreign currency are translated to the functional currency of the Group at exchange rates as of the transaction dates. Monetary assets and liabilities denominated in foreign currency as of the reporting date are translated into the functional currency at the exchange rate as of the said date. Exchange rate differences with respect to monetary items are the differences between the amortized cost in the functional currency as of the start of the year, adjusted for the effective interest during the year, and the amortized cost in foreign currency, translated at the exchange rate as of the end of the year. Non-monetary items denominated in foreign currency and measured at historical cost, are translated using the exchange rate as of the transaction date. Exchange rate differences arising from translation into the functional currency are recognized on the statement of operations as financial expenses. C. Derivative and Non-derivative financial instruments 1. Non-Derivative financial instruments a. Non-derivative financial assets Non-derivative financial assets include: cash and cash equivalents, short term deposits and other receivables. Cash and cash equivalents include cash balances available for immediate use and call deposits. Cash equivalents include short-term highly liquid investments (with original maturities of three months or less) that are readily convertible into known amounts of cash and are exposed to insignificant risks of change in value. b. Non-derivative financial liabilities Non-derivative financial liabilities include: accounts payables and other accounts payable. Initial recognition of financial liabilities: The Group initially recognizes debt instruments issued as they are created. Other financial liabilities are initially recognized on the trade date on which the Group becomes party to contractual terms of the instrument. Financial liabilities are initially recognized at fair value less any attributable transaction costs. Subsequent to initial recognition, financial liabilities are measured at amortized cost using the effective interest method. Transaction costs directly attributable to an expected issuance of an instrument that will be classified as a financial liability are recognized as an asset as part of deferred expenses in the statement of financial position. These transaction costs are deducted from the financial liability upon their initial recognition, or are amortized as financing expenses in the statement of operations when the issuance is no longer expected to occur. De-recognition of financial liabilities: Financial liabilities are de-recognized upon expiration of the Group’s liability, as set forth in the agreement, or when discharged or cancelled. 2. Derivative financial liabilities The Group holds derivative financial instruments that do not serve hedging purposes, including separable embedded derivatives. Measurement of derivative financial instruments Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are accounted for as described below. The changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these derivatives is based on an evaluation prepared by external experts, and classified as level 3. D. Intangible assets 1. Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. The expenditure capitalized in respect of development activities includes the cost of materials, direct labor and overhead costs that are directly attributable to preparing the asset for its intended use, and capitalized borrowing costs. Other development expenditure is recognized in profit or loss as incurred. In subsequent periods, any capitalized development expenditure is measured at cost less accumulated amortization and accumulated impairment losses. As the Group has not met the criteria mentioned above, all development costs are currently recognized in profit and loss as expense. 2. Other intangible assets Other intangible assets, including in-process research and development in respect of the Company’s acquisition of TyrNovo (see also Note 4), which have infinite useful lives, are measured at cost less accumulated impairment losses. 3. Amortization Amortization is a systematic allocation of the amortizable amount of an intangible asset over its useful life. The amortizable amount is the cost of the asset less its residual value. Amortization is recognized in profit or loss on a straight-line basis, over the estimated useful lives of the intangible assets from the date they are available for use, since these methods most closely reflect the expected pattern of consumption of the future economic benefits embodied in each asset. Goodwill and intangible assets having an indefinite useful life are not systematically amortized but are tested for impairment at least once a year. Internally generated intangible assets are not systematically amortized as long as they are not available for use, i.e. they are not yet on site or in working condition for their intended use. Accordingly, these intangible assets, such as development costs, are tested for impairment at least once a year, until such date as they are available for use. Amortization methods, useful lives and residual values are reviewed at the end of each reporting year and adjusted if appropriate. The Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether events and circumstances continue to support the decision that the intangible asset has an indefinite useful life. E. Loss per share The Group presents loss per share data for its ordinary share capital. Loss per share is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding during the period. F. Share-based payment transactions The grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. G. Financing income and expense Finance income comprises changes in the fair value of the financial liability through profit and loss, and income from short term deposits. Finance expenses include loss from exchange rate differences. Interest expense is recognized, using the effective interest method. In the statements of cash flows, interest received and interest paid are presented as part of cash flows from financing activities. H. Equity Incremental costs directly attributable to an expected issuance of an instrument that will be classified as equity are recognized as an asset in deferred expenses in the statement of financial position. The costs are deducted from the equity upon the initial recognition of the equity instruments, or are expensed as financing expenses in the statement of operations when the issuance is no longer expected to take place. I. Issuance of units of securities The consideration received from the issuance of units of securities is attributed initially to financial liabilities that are measured each period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair value. The remaining amount is the value of the equity component. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described above. J. Employee benefits The Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance companies or with funds managed by a trustee, and they are classified as defined contribution plans and as defined benefit plans. A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Other long-term employee benefits The Group’s net obligation in respect of defined benefit plans is calculated separately for each plan by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The calculation of defined benefit obligations is performed annually by a qualified actuary using the projected unit credit method. When the calculation results in a potential asset for the Group, the recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. To calculate the present value of economic benefits, consideration is given to any applicable minimum funding requirements. Re-measurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in OCI. The Group determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss. K. New standards and interpretations not yet adopted IFRS 15, Revenue from contracts with customers IFRS 15 replaces the current guidance regarding recognition of revenues and presents a comprehensive framework for determining whether revenue should be recognized and when and at what amount. IFRS 15 is applicable for annual periods beginning on or after January 1, 2018 and earlier adoption is permitted. As the Group has not commenced serving activity in its opinion there would be no effect on the financial statements. IFRS 9 (2014), Financial Instruments IFRS 9 (2014) replaces the current guidance in IAS 9, Financial Instruments: Recognition and Measurement. IFRS 9 (2014) includes revised guidance of the classification and measurement of financial instruments, expected ‘credit loss’ model for calculating impairment for most financial assets, and new guidance and requirements with respect to hedge accounting. IFRS 9 (2014) is applicable for annual periods beginning on or after January 1, 2018 and earlier adoption is permitted. The Group has examined the effects of applying IFRS 9 (2014), and in its opinion the effect on the financial statements will be immaterial. IFRS 16, Leases IFRS 16 replaces IAS 17, Leases IFRS 16 is applicable for annual periods as of January 1, 2019, with the possibility of early adoption, so long as the Group has also early adopted IFRS 15, Revenue from Contracts with Customers The Group decided not to early adopt IFRS 16 and will examine its adoption’s effects in the future. IFRIC 22, Foreign Currency Transactions and Advance Consideration The interpretation provides that the transaction date for the purpose of determining the exchange rate for recording a foreign currency transaction that includes advanced consideration is the date of initial recognition of the non-monetary asset/liability from the prepayment. If there are multiple payments or receipts in advance, a transaction date is established for each payment or receipt. IFRIC 22 is applicable for annual periods beginning on or after January 1, 2018 and earlier adoption is permitted. The Group has examined the effects of applying IFRIC 22, and in its opinion there will be no effect on the financial statements.

Acquisition of Subsidiary

Acquisition of Subsidiary	12 Months Ended
	Dec. 31, 2017
Acquisition of Subsidiary [Abstract]
Acquisition of Subsidiary	Note 4 – Acquisition of Subsidiary On January 13, 2017, the Company completed its acquisition from Goldman Hirsh Partners Ltd (“GHP”) of a controlling interest in TyrNovo, a privately owned Israeli company, which is developing a small molecule that has demonstrated the potential to overcome resistance to multiple anti-cancer drugs. Pursuant to the terms of the transaction, the Company issued to GHP, 11,292,508 of its Ordinary Shares (the “Consideration Shares”) and paid GHP aggregate cash proceeds of approximately USD 2 million (the “Cash Consideration”) in exchange for 9,570 Ordinary Shares in TyrNovo, that represent approximately 65% of TyrNovo’s shares. In addition, the Company was assigned a loan in the amount of USD 101,157 which had been made by GHP to TyrNovo, (the “TyrNovo Acquisition. USD 167,157 of the Cash Consideration is being held back by the Company pending the fulfillment of certain conditions as agreed to between the Company and GHP. All of the Consideration Shares were placed in escrow in order to ensure the fulfillment of certain post-closing undertakings and to satisfy indemnification claims and other liabilities the Company may become subject to as a result of the TyrNovo Acquisition. The acquisition was accounted for as an asset purchase as it does not meet the definition of a business combination in accordance with IFRS 3. In the period from January 13, 2017 to December 31, 2017, TyrNovo contributed losses of USD 2,088 thousand to the Group’s results. Management estimates that if the acquisition had taken place on January 1, 2017, there would not have been a material change to the consolidated loss. A. Consideration The following summarizes the acquisition date fair value of each major class of consideration: USD thousands Cash 2,000 Equity instruments issued (11,292,508 Ordinary Shares) (1) 1,800 Assignment of loan to the Company (101 ) Total consideration transferred 3,699 (1) Equity instruments issued The fair value of the Ordinary Shares issued was based on the listed share price of the Group at January 11, 2017 of approximately USD 0.16 per share (USD 3.14 per ADS). B. Identifiable assets acquired and liabilities assumed The following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition: USD thousands Current assets 21 Fixed assets, net 3 Intangible assets (2) 6,172 Short-term credit from bank (16 ) Trade payables (123 ) Other payables (212 ) Long-term related parties (130 ) Total net identifiable assets 5,715 (2) In-process research and development Purchased in-process research and development expense represents the value assigned to research and development projects, which were commenced but not yet completed at the date of acquisition. Technological feasibility for these projects has not been established and they have no alternative future use in research and development activities or otherwise. C. Non-controlling interests Non-controlling interests are presented based on their proportionate interest in the recognized amount of the assets and liabilities of TyrNovo.

Subsidiaries

Subsidiaries	12 Months Ended
	Dec. 31, 2017
Subsidiaries [Abstract]
Subsidiaries	Note 5 - Subsidiaries The following is condensed information regarding the subsidiaries directly held by the Company: Amounts provided by the Company to the subsidiary Incorporated and operates in Israel Group’s ownership equity Company’s direct ownership of equity Loans Guarantees Total investment in subsidiary USD thousands Kitov Pharmaceuticals Ltd. (1) Israel 100 % 100 % (19,481 ) - (19,748 ) TyrNovo Ltd. Israel 64.72 % 64.72 % (1,597 ) - 2,404 (1) With regards to its merger with the Company, see also Note 1.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2017
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Note 6 - Cash and Cash Equivalents As of December 31 2017 2016 USD thousands Balance in USD 3,322 4,980 Balance in other currencies *625 1,778 Total cash and cash equivalents 3,947 6,758 (*) Including an amount of USD 50 thousand as guarantee for the Group’s leases. See also Note 13A1.

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2017
Other Current Assets [Abstract]
Other Current Assets	Note 7 - Other Current Assets As of December 31 2017 2016 USD thousands Government authorities 171 151 Prepaid expenses and other receivables * 377 90 Total other current assets 548 241 (*) Including an amount of USD 166 thousand, as of December 31, 2017, representing deposits entrusted to Israeli court on behalf of related parties pursuant to an indemnification obligation of the Company, in respect of an investigation of the Israeli Security Authority against the Company. See also Note 13B3.

Other Payables

Other Payables	12 Months Ended
	Dec. 31, 2017
Other Payables [Abstract]
Other Payables	Note 8 - Other Payables As of December 31 2017 2016 USD thousands Due to related parties 1,059 548 Due to GHP (note 4) 167 - Accrued expenses 326 76 Government authorities 107 - Payroll related payables 87 134 Deferred income (1) 95 - 1,841 758 (1) On March 2, 2017, the Group signed an agreement with a distributor granting exclusive right and license to manufacture, distribute and sell certain of the Groups products in South Korea, in accordance with the agreement between the parties.

Equity

Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Equity	Note 9 - Equity A. The Company’s share capital As of December 31, 2017 As of December 31, 2016 Number of shares thousand Authorized Issued and paid-in Authorized Issued and paid-in Ordinary shares, no par value 5,000,000 224,443 5,000,000 153,237 Class A preferred shares, no par value 2,000 - 2,000 - Class B preferred shares, no par value 2,000 - 2,000 - Class C preferred shares, no par value 2,000 - 2,000 - Class D preferred shares, no par value 2,000 - 2,000 - Class E preferred shares, no par value 2,000 - 2,000 - B. Changes in share capital during the year For the year ended December 31 2017 2016 2015 Number of shares thousand Issued as at January 1 153,237 77,756 5,972 Issuance of ADSs 48,635 47,576 63,178 Issuance of shares *11,293 - 6,388 Share issuance deriving from a strategic cooperation agreement - 3,010 597 Share issuance due to meeting of milestone - - 1,379 Share based payments 11,278 669 - Exercise of warrants - 24,226 242 Issued as at December 31 224,443 153,237 77,756 (*) See Note 4. C. Financing rounds 1. In July 2017, in a registered direct offering on the NASDAQ, the Company raised USD 3.5 million gross (approximately USD 3.1 million net of placement agent fees and other offering related expenses). In this registered direct offering, the Company issued 2,431,746 ADSs in a concurrent private placement and 1,215,873 non-listed warrants to purchase 1,215,873 ADSs. Each non-listed warrant is exercisable until January 14, 2023 at an exercise price of USD 1.50 per ADS. The ADS’s issued were recorded in equity and in an amount of USD 2,174 thousand. The warrants were considered a derivative instrument and are recorded as a liability. See also Note 20B. 2. In July 2016, in a public offering on the NASDAQ, the Company raised USD 12 million (approximately $10.0 million net of placement agent fees and other offering related expenses). In the public offering the Company issued securities as follows: (i) 2,378,823 Class A units - comprised of 2,378,823 ADSs and 2,378,823 Series A warrants to purchase 2,378,823 ADSs, and (ii) 1,150,589 Class B units - comprised of 1,150,589 prefunded Series B warrants to purchase 1,150,589 ADSs and 1,150,589 Series A warrants to purchase 1,150,589 ADSs. The July 2016 public offering was completed at a price of USD 3.40 per unit. Each Series A warrant is exercisable through November 25, 2020 for an exercise price of USD 3.78, as adjusted following the July 2016 offering. All of the Series B warrants had been exercised by August 31, 2016 for an exercise price of USD 0.01 per ADS. In addition, the Company granted representatives of the placement agent non-traded warrants to purchase up to 141,176 ADSs for an exercise price of USD 4.08. 3. In November 2015, in a public offering on the NASDAQ, the Company raised USD 13.0 million, (approximately USD 10.6 million after deduction of underwriters’ commissions and public offering related expenses). On November 20, 2015, the Company’s ADSs and warrants commenced trading on the NASDAQ under the symbols KTOV and KTOVW, respectively. The public offering was completed on November 25, 2015. In the November 2015 public offering the Company issued 3,158,900 ADSs and 3,158,900 Series A warrants to purchase 3,158,900 ADSs. Each ADS represents 20 ordinary shares with no par value. Each warrant enables the purchase of 1 ADS. The public offering was completed at a price of USD 4.13 for a unit of 1 ADS and 1 warrant. Each warrant is exercisable for a period of 5 years for an initial exercise price of USD 4.13, which has since been adjusted to USD 3.78. In addition, the Company granted the underwriters the right to sell within 45 days up to 473,835 ADSs and/or 473,835 Series A warrants at the same terms as the public offering (of which the underwriters exercised the right to sell 220,074 warrants). The Company also granted the underwriters non-traded warrants to purchase up to 157,945 ADSs for an exercise price of USD 4.956. D. Other equity transactions 1. On October 30, 2017, the Company issued to a vendor of the Company, in consideration for services provided by the vendor to the Company, 67,367 ADSs (representing 1,347,340 ordinary shares of the Company). The fair value of the ADSs was measured at USD 96 thousand, out of which, USD 83 thousand were recorded as an expense under general and administrative expenses, and USD 13 thousand were deferred and recorded under prepaid expenses (under “other current assets”) in the statement of financial position. 2. During October and December 2017, the Company issued 9,930,672 ordinary shares on account of vested RSUs. See also Note 10. 3. During 2016, the Company issued 669,100 shares to service providers for services granted. The fair value of the shares was measured at the fair value of the services, and amounted to USD 103 thousand. 4. In May 2016 the Company issued 3,009,888 shares to Dexcel Ltd. following meeting a milestone in accordance with the agreement between the Company and Dexcel Ltd. The fair value of the shares was USD 500 thousand. 5. During 2016 the Company issued 1,214,340 shares derived from the exercise of Series A warrants, for proceeds of USD 302 thousand. E. Non-controlling interests The following table summarizes the information relating to a subsidiary that has material non-controlling interests, before any intra-group eliminations: December 31, 2017 TyrNovo Ltd. Non-controlling interests percentage 35.28 % Non-current assets 3 Current assets 158 Current liabilities (2,676 ) Net assets (2,515 ) Net assets attributable to non-controlling interests (887 ) Loss 2,088 Loss allocated to non-controlling interests 736

Share-based Payment Arrangement

Share-based Payment Arrangements	12 Months Ended
	Dec. 31, 2017
Share-based Payment Arrangements [Abstract]
Share-based Payment Arrangements	Note 10 - Share-based Payment Arrangements A. On August 15, 2017, the Company’s Board of Directors approved grants of 348 thousand RSUs and 580 thousand options. The RSUs and/or options have a vesting period of 3 years from the commencement of the service provider’s engagement, with a one-year cliff for the first one-third of the vested amount, and over 8 quarters thereafter. The exercise period is 7 years from the date of the grant. The options shall have an exercise price equals to NIS 0.3297 per one ordinary share. 580 thousand options and 174 thousand RSUs were fully vested at the time of the grant. The fair value of these RSUs and options at the date of the grant was measured at USD 32 thousand and USD 31 thousand, respectively. In addition, on August 15, 2017, the Company’s Board of Directors approved grants of 836 thousand RSUs and 320 thousand options. The RSUs have a vesting period of 3 years from November 25, 2015, with a one-year cliff for the first one-third of the vested amount, and over 8 quarters thereafter. The exercise period is 7 years from the date of the grant. The options shall have an exercise price equal to NIS 0.7884 per one ordinary share and shall have a vesting period of 3 years from May 22, 2016. The exercise period is 7 years from the date of the grant. 160 thousand options and 558 thousand RSUs were fully vested at the time of the grant. The fair value of these RSUs and options at the date of the grant was measured at USD 76 thousand and USD 15 thousand, respectively. In June 2017, the Company’s board of directors decided to amend the Company’s 2016 Equity-Based Incentive Plan (the “Plan”) to increase the number of Ordinary Shares available for issuance thereunder by an additional 38,000,000 Ordinary Shares. No other amendments were made to the Plan. On August 1, 2017, the Company’s board of directors approved grants of 12,161 thousand RSUs and 8,790 thousand options. The options have an exercise price equals to NIS 0.3297 per one ordinary share. The RSUs and/or options have a vesting period of 3 years from the commencement of the Officer’s or Director’s engagement, with a one-year cliff for the first one-third of the vested amount, and over 8 quarters thereafter. The exercise period is 7 years from the date of the grant. 438 thousand RSUs and 396 thousand options were fully vested at the time of the grant. The fair value of these RSUs and options at the date of the grant was measured at USD 1,326 thousand and USD 592 thousand, respectively. In June 2016, the Company’s shareholders approved the grant of options to the chairman of the board of directors in order to maintain a number of options reflecting a certain percentage of holdings in the Company, subject to certain conditions as determined by the board of directors . In May 2016 and June 2016, the Company granted 7,281,370 options to the chairman of board of directors, chief executive officer, chief financial officer, senior employees and a service provider. Each option may be exercised into one ordinary share, at an exercise price of NIS 0.7884 ($0.205) per share over a vesting period of 3 years. The exercise period is 8 years from date of issuance provided, however that with respect to 5,957,485 thousand of the options granted to directors of the Company, no options were exercisable prior to the Company’s adoption of a revised compensation policy in accordance with the Companies Law. In July 2017 a revised compensation policy was adopted. In February 2015, the Company’s board of directors decided to grant 44,786 options to two consultants in return for their services. The options were exercisable into 44,786 shares for an exercise price of NIS 4.00 for a period of 24 months. The options vested immediately on the grant date, May 14, 2015. The fair value of these options at the date of granting was measured at USD 31 thousand. During 2017 these options expired. The fair value of these options and RSUs at the dates of grants was measured at USD 2,071 thousand during the year ended December 31, 2017. The Company recorded an expense of USD 2,196 thousand, of which USD 1,905 thousand are to key management personnel. C. The number and weighted average exercise prices (in NIS) of share options are as follows: Weighted average exercise price Number of options 2017 2016 2015 2017 2016 2015 Outstanding at January 1 0.83 0.81 0.78 10,394,915 3,510,729 3,872,359 Expired during the year 4 0.81 0.80 44,786 2,865,943 406,416 Granted during the year 0.33 0.79 4.00 9,690,299 9,750,129 44,786 Outstanding at December 31 0.36 0.83 0.81 20,040,428 10,394,915 3,510,729 Exercisable at December 31 0.32 0.96 0.83 14,177,578 2,269,808 3,285,729 The options outstanding at December 31, 2017 had an exercise price in the range of NIS 0.33 – NIS 1.20 (2016 - NIS 0.79 – NIS 4), and weighted average contractual life of 7.2 years (2016 – 7.7 years). D. The number of RSUs are as follows: Number of RSUs 2017 Outstanding at January 1 - Granted during the year 13,345,205 Vested during the year (9,930,671 ) Outstanding at December 31 3,414,534 E. Options to service providers were measured at the fair value of the service, when available. The fair value of the Company’s share options granted to employees, directors and service providers, where fair value of service was not measurable, was measured using the binominal model, using the fair value of the traded warrants with similar terms, making some adjustments to reflect the specific terms of the options based on the expected duration. The following assumptions were used : 2017 2016 Share Price - NIS 0.326-0.388 0.21-0.26 Option price - USD 0.164-0.191 1.07-1.42 Expected volatility (%) 80.65-80.91 - Expected duration (years) 6.77-6.97 4-8 Dividend yield (%) - - Risk free rate interest rate (%) 1.36-1.39 N/A F. Expenses recognized in the financial statements: For the year ended December 31 2017 2016 2015 USD thousands Total share-based expense recognized 2,308 400 59

Transactions and Balances with

Transactions and Balances with Related Parties	12 Months Ended
	Dec. 31, 2017
Transactions and Balances with Related Parties [Abstract]
Transactions and Balances with Related Parties	Note 11 - Transactions and Balances with Related Parties In addition to their salaries, the Group also provides non-cash benefits to directors and executive officers, and contributes to a post-employment defined contribution plan on behalf of employees. Certain executive officers are entitled to termination benefits of up to 6 monthly salaries or fees. Executive officers also participate in the Group’s share option programs. For further information see Note 10 regarding share-based payments. The Company made payments to key management personnel: For the year ended December 31 2017 2016 2015 USD thousands Short - term employee benefits 2,522 1,336 1,207 Post-employment benefits 137 25 185 Share based payments 1,905 244 7 4,564 1,605 1,399

Settlement with a Minority Shar

Settlement with a Minority Shareholder of Tyrnovo	12 Months Ended
	Dec. 31, 2017
Settlement With A Minority Shareholder Of Tyrnovo [Abstract]
Settlement with a minority shareholder of TyrNovo	Note 12 – Settlement with a minority shareholder of TyrNovo On February 9, 2017, subsequent to the acquisition of TyrNovo (see Note 4), the Company, TyrNovo and Taoz - Company for Management and Holdings of Companies Ltd. (“Taoz”), a shareholder owning approximately 4% of TyrNovo, entered into a settlement arrangement in response to a motion filed by Taoz on January 19, 2017. Pursuant to the settlement arrangement, the parties agreed, among other matters, as follows: Taoz is entitled to be issued an additional 77 ordinary shares of TyrNovo, representing 0.5% of the issued and outstanding share capital of TyrNovo immediately following this issuance. The shares were issued in February 2017 and were measured at a fair value of USD 29 thousand. Taoz has the right during a defined period to invest an additional USD 1,750,000 (the “Deferred Investment”) by way of convertible loans, with conversion terms defined under various circumstances, including the possibility of conversion at a price per share reflecting a 30% discount off the price per share paid in a subsequent financing round, and the possibility of conversion at a price per TyrNovo share reflecting a TyrNovo company valuation of USD 13,500,000. In the event that a defined Milestone is achieved, and Taoz did not invest the Deferred Investment, then the Company has the right to acquire all of Taoz’s holdings in TyrNovo at a price per share of USD 476.48. The Company provided to Taoz a put option to sell to the Company up to 50% of the TyrNovo shares issued to Taoz, exercisable during a period of 90 days from the publication by TyrNovo of the results of Phase I clinical trials, for a price per TyrNovo share equal to US$1,600, either in ordinary shares of the Company or, at the Company’ sole discretion, in cash; upon the expiration of the 90 day exercise period, the put option, if not exercised by Taoz, shall expire and no longer be valid. The rights granted to Taoz by the Company were valued at the date of agreement at USD 1,000 thousand and were charged to Other Expenses in these financial statements. The value of these rights as of December 31, 2017 was estimated at USD 1,030 thousand. The net change in value of this liability in the amount of USD 30 thousand was charged to Finance Expenses in the financial statements. Included in other expenses is also USD 29 thousand value of shares issued to Taoz, see notes above. Regarding Valuation techniques and significant unobservable inputs, see note 20B.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2017
Commitments and Contingent Liabilities [Abstract]
Commitments and contingent liabilities	Note 13 – Commitments and contingent liabilities A. Commitments 1. The Company has an annual commitment under lease agreements for its office premises through to the end of 2020 and for car leases through mid - 2021, of approximately NIS 702 thousand per year (approximately USD 203 thousand). 2. Certain of the Company’s senior executives are entitled to annual and special bonuses under the terms of their employment and consulting agreements. These bonuses will become due upon the achievement of certain milestones, including fund raising, merger transactions, and agreements for the commercialization of the Company’s products. These financial statements include bonuses in the amount of USD 1,056 thousand for the year ended December 31, 2017, and USD 848 thousand for the year ended December 31, 2016, of which USD 363 thousand, respectively, were included in the statement of changes in equity as part of issuance costs of ADSs in 2016. 3. Certain of the Company’s senior executives are entitled to retirement grants under the terms of their employment and consulting agreements. These grants are measured based on the time of service and their monthly pay. These financial statements include a liability due to these grants of USD 492 thousand and USD 256 thousand, as of December 31, 2017 and 2016. 4. Kitov Pharma’s subsidiary, TyrNovo, has obligations to the Israel Innovation Authority (hereinafter: “IIA”) with respect to grants it received from the IIA in connection with TyrNovo’s technology, in an aggregate amount of approximately NIS 5.5 million (USD 1.6 million). The requirements and restrictions for such grants are found in the Encouragement of Research, Development and Technological Innovation in Industry Law 5744-1984 and the IIA’s rules and guidelines and the terms of these grants. In general, a recipient company is obligated to pay the IIA royalties from the revenues generated from the sale of products and related services developed as a result of, a research and development program funded by the IIA (currently a yearly rate of 3% to 6%), up to the aggregate amount of the total grants received by the IIA, plus annual interest. The technologies licensed to TyrNovo by Yissum were developed, at least in part, with funds from IIA grants, and accordingly is obligated to pay royalties on sales of any of its IIA funded products and related services. As of December 31, 2017, the maximum royalty amount that would be payable by TyrNovo, excluding interest, is approximately NIS 5.5 million (USD 1.6 million), and, as of such date, TyrNovo had not paid any royalties to the IIA. 5. TyrNovo has entered into a license agreement (the “License Agreement”) with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (hereafter “Yissum”) dated August 15, 2013, as amended. In accordance with the License Agreement, Yissum granted the Company an exclusive license to commercialize, exploit, develop, manufacture, market, import, export, distribute, offer to sell, or sell products, that are derived from Yissum’s licensed technology. In consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license: (i) Royalties at a rate of three percent (3%) of net sales. (ii) Sublicense fees at a rate of twelve percent (12%) of sublicense consideration. In addition, Yissum is entitled to receive an Exit Fee of 12% of the transaction proceeds in the event of certain pre - defined transactions set forth in the License Agreement. B. Claims 1. In December 2015, a lawsuit and a motion to approve such lawsuit as a class action was filed against the Company and its directors by shareholders who were holding the Company’s Tel Aviv Stock Exchange listed securities before the offering mentioned in Note 9C(3), claiming damages for the purported class in the motion totaling NIS 16.4 million (USD 4.3 million) due to the said offering (the “Motion”). The Company delivered its response to the court in accordance with applicable law. A preliminary hearing held by the court on September 12, 2016 and subsequently the court set a schedule for the submission by the petitioners of a motion for discovery, and any responses to such motion. An additional preliminary hearing was held on February 7, 2017. On October 24, 2017 the court issued a ruling to stay proceedings in this matter until January 15, 2018 due to the ongoing ISA Investigation. This stay was subsequently extended by the court, which ruled that the evidentiary hearing shall not be rescheduled and that the stay of proceedings shall remain in place pending delivery of a notice to the court by the ISA by no later than May 15, 2018 with respect to an update on the ISA Investigation. 2. On November 8, 2016, a shareholder of the Company submitted a request to the court in connection with the Motion to be excluded from the purported class and claiming to have independent causes of action and claims of approximately NIS 1 million (the “Petition to Exclude”). The Company responded to the court as required, and, amongst other arguments, the Company noted that such shareholder cannot petition to be excluded from the purported class. The court ordered the shareholder to respond and he has done so. The shareholder has not submitted any independent lawsuit against the Company, and the Company is of the view that such shareholder’s claims are identical to the asserted claims for damages in the Motion. The Company’s management rejects the claims asserted in the Motion as well as in the Petition to exclude, and, in consultation with its legal advisors, believes that the likelihood of the Company not incurring any financial obligation as a result of this class action exceeds the likelihood that the Company will incur a financial obligation. Therefore, no provision for this matter was recorded in these financial statements. 3. In February 2017 the Company announced that the Israeli Securities Authority has begun a formal investigation into, amongst other matters, the Company’s public disclosures in connection with the Data Monitoring Committee (DMC) appointed in connection with the Company’s Phase III trial of KIT-302, the results of which were announced in December 2015, and what information regarding the DMC was disclosed publicly by Kitov. A DMC is generally an external independent group of experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing, and, in the case of the KIT-302 Phase III clinical trial, was established in order to analyze the preliminary results of the initial patient group enrolled in the clinical trial and determine the number of additional patients, if any, that Kitov might have needed to recruit in order to demonstrate statistical validity, and to meet the primary end point of the clinical trial. In February 2017, four lawsuits and motions to approve the lawsuits as a class action lawsuit (each, a “Motion”), were filed against the Company and certain of its office holders at the Tel Aviv District Court (Economic Division), and served on the Company, with each Motion relating to the above noted formal investigation by the Israeli Securities Authority (ISA) into the Company’s public disclosures (the 2017 Motions”). One of these motions was subsequently withdrawn. The petitioners in one of the motions petitioned the court to dismiss the other 2 of the 2017 Motions (“Petition for Dismissal”). On December 19, 2017 the court granted the Petition for Dismissal and dismissed the other remaining 2017 Motions. The remaining motion was filed against the Company, the Company’s executive directors and certain of its present and former directors, by certain shareholders who are requesting to act as representatives of all shareholders of record from December 10, 2015 until February 6, 2017. The plaintiffs allege, among other things, that the Company included misleading information in its public filings which caused the class for which the plaintiffs are seeking recognition, an aggregate loss of approximately NIS 29 million (approximately US$ 8 million). The Company and other defendants have not yet delivered their response to the court, and will do so in accordance with applicable law and the court’s instructions. Under applicable Israeli law, a motion to approve a lawsuit as a class action initially needs to be approved as such by the court. Only after such approval is granted by the court, will the court proceed to the second stage of hearing the underlying claims of the class action lawsuit. On February 7, 2017, a holder of the Company’s securities listed on the NASDAQ filed in the United States District Court (Southern District of New York), a federal securities class action relating to the above noted formal investigation by the ISA into the Company’s public disclosures against the Company, its CEO and CFO, seeking unspecified damages and relief in connection with, amongst other things, damages alleged to have occurred due to the purchasers of the Company’s securities in the Company’s initial public offering in the USA on November 20, 2015, as well as in open market purchases, as a result of the Company allegedly including misleading information in its public filings. An amended complaint was filed on June 19, 2017, which complaint limited the scope of its claims as compared to the original complaint. On August 2, 2017, the Company filed a motion to dismiss the amended complaint in its entirety. In addition, on September 20, 2017, the Company filed a letter motion requesting a conference on the issue of whether this litigation should be dismissed. On September 21st, the court granted the Company’s request, and on November 7th, the court ordered that the issues raised in the letter motion would be considered together with and supplementing our motion to dismiss. No decision has yet been rendered on the motion to dismiss. On February 10, 2017, a holder the Company’s securities listed on the NASDAQ filed in the Superior Court of the State of California, a securities class action relating to the above noted formal investigation by the ISA into the Company’s public disclosures, against the Company, its CEO and CFO and the underwriters in the Company’s initial public offering in the USA on November 20, 2015, seeking unspecified damages and relief in connection with, amongst other things, damages alleged to have occurred due to the purchasers of the Company’s securities in such public offering as a result of the Company allegedly including misleading information in its public filings. On March 20, 2017, a holder the Company’s securities listed on the NASDAQ filed in the Superior Court of the State of California, a securities class action against the Company, its CEO and CFO and the underwriters in the Company’s initial public offering in the USA on November 20, 2015, seeking unspecified damages and relief in connection with, amongst other things, damages alleged to have occurred due to the purchasers of the Company’s securities in such public offering as a result of the Company allegedly including misleading information in its public filings. On April 6, 2017, the Superior Court of the State of California for the County of San Mateo entered an order consolidating the two California putative class actions. An amended complaint was filed on or about June 5, 2017. On December 15, 2017, the Company filed a motion to stay discovery pending the resolution of the ISA Investigation. Following Plaintiffs’ opposition to our motion on January 5, 2018 and our reply in further support on January 16, 2018, the court ruled in our favor after arguments on January 29th, 2018 staying discovery by Plaintiffs against the Company and the individual defendants until June 1, 2018, at which point the parties are to update the court on the status of the ISA’s investigation. Discovery against the underwriters is continuing. The Company’s management rejects the claims in all of the aforesaid Motions and class action lawsuits. At this preliminary stage the Company is unable, with any degree of certainty, to make any evaluations or any assessments with respect to the Motions’ and/or lawsuits in the U.S.A. and in Israel as to the probability of success or the scope of potential exposure, if any. Therefore, no provision for this matter was recorded in these financial statements.

Research and Development Expens

Research and Development Expenses	12 Months Ended
	Dec. 31, 2017
Research and Development Expenses [Abstract]
Research and Development Expenses	Note 14 - Research and Development Expenses Research and development expenses include salaries and consulting expenses for development of drug formulation and for non-clinical, clinical, regulatory and project management work required for the Group’s drug portfolio.

General and Administrative Expe

General and Administrative Expenses	12 Months Ended
	Dec. 31, 2017
General and Administrative Expenses [Abstract]
General and Administrative Expenses	Note 15 - General and Administrative Expenses For the year ended December 31 2017 2016 2015 USD thousands Employee and officer compensation 1,984 1,131 515 Share-based payments (see also Note 10) 1,224 121 26 Legal fees in connection with ISA investigation and class action lawsuits (see also note 13B) 893 84 - Other professional consulting 1,306 1,059 728 Board member remuneration and insurance 552 155 67 Rent and office maintenance 196 94 95 Travel 131 99 13 Car expenses 64 42 27 Depreciation 4 2 1 Other 38 216 37 6,392 3,003 1,509

Other Expenses

Other Expenses	12 Months Ended
	Dec. 31, 2017
Others Expenses [Abstract]
Other Expenses	Note 16 – Other Expenses During 2017 the Company recorded an amount of USD 1,029 thousand in its financial statements under Other Expenses, with regards to rights granted to Taoz as part of the Company’s settlement with Taoz, regarding the acquisition of TyrNovo. See also Note 12.

Finance Expense (Income)

Finance Expense (Income)	12 Months Ended
	Dec. 31, 2017
Finance Expense (Income) [Abstract]
Finance Expense (Income)	Note 17 – Finance Expense (Income) For the year ended December 31 2017 2016 2015 USD thousands Net change in fair value of derivatives Expenses * 1,049 5,160 - Income - (141 ) (94 ) Net change in fair value of derivatives 1,049 5,019 (94 ) * This expense is related to the fair value adjustments of warrants. The warrants include an anti-dilution provision whereby the exercise price of the warrants are subject to “weighted average” ratchet anti-dilution provision, so that upon future issuance of the Company’s ADSs or an equivalent number of ordinary shares, subject to specified exceptions, at a price less than the exercise price then in effect, the exercise price will be reduced. The ratchet for the 2017 warrants expired on January 14, 2018, and the ratchet for the 2016 Series A warrants expired on November 25, 2016. For the year ended December 31 2017 2016 2015 USD thousands Finance expense Fees and interest expense 26 6 3 Loss from exchange rate differences, net - 55 79 Credit allocation fee ** - - 141 Warrant issuance costs - - 4 26 61 227 ** In August 2015 the Company entered into loan agreements with several third parties (the “Lenders”) pursuant to which, they extended the Company loans of USD 430 thousand. The loans were repaid in November 2015 with an addition of credit allocation fees in the amount of $141 thousand. For the year ended December 31 2017 2016 2015 USD thousands Finance income Income from exchange rate differences, net (22 ) - - Interest income from short term deposits (106 ) (138 ) - (128 ) (138 ) -

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2017
Taxes on Income [Abstract]
Taxes on Income	Note 18 - Taxes on Income A. Corporate tax rate The tax rate applicable to the Group for 2017 is 24%. The tax rate in 2018 is expected to be 23%. B. The Company and its subsidiaries incurred losses in 2017, as well as carry-forward losses from previous years, which are not expected to be utilized in the foreseeable future. Therefore the Group companies did not record current taxes or deferred taxes. The carry-forward loss for tax purposes for the Company and its subsidiaries, and the unrecognized deferred taxes from research and development expenses, amounts to USD 28.2 million as of December 31, 2017 (2016 – USD 13.2 million, 2015 – USD 9 million). C. The Company’s 2012 tax assessment is deemed finalized, pursuant to section 145 of the Israeli Income Tax Ordinance. The subsidiary’s 2012 tax assessment is deemed finalized, pursuant to section 145 of the Israeli Income Tax Ordinance.

Employee Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2017
Employee Benefits [Abstract]
Employee benefits	Note 19 - Employee benefits A. Employee benefits include post-employment benefits and short term benefits. Post-employment benefits are part of key management compensation – see Note 11 on related parties. Balances include: December 31. 2017 2016 USD thousands USD thousands Short-term benefits 112 670 Post-employment benefits 492 256 B. Post-employment benefit plans – defined contribution plan The Company has a defined contribution plan in respect of the Company’s liability in respect of its employees who are subject to Section 14 of the Severance Pay Law – 1963. Year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Amount recognized as expense in respect of defined contribution plan 52 39 25

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2017
Financial Instruments [Abstract]
Financial Instruments	Note 20 – Financial Instruments A. Cash and cash equivalents and short term deposits The Group held cash and cash equivalents and short term deposits of USD 7,435 thousand at December 31, 2017 (2016 – USD 14,657). These are held with banks, which are rated A2, based on Moody’s Rating Agency ratings. The short term deposits, mainly in USD, bear fixed interest ranging between 0.14% - 1.6%. The carrying amount of cash and cash equivalents and short term deposits approximate their fair value. B. Fair value hierarchy of financial instruments measured at fair value December 31, 2017 Level 1 Level 2 Level 3 Total USD thousands Financial liabilities Warrants (see Note 9(C)(1)) - - 2,012 2,012 Put option to Taoz (see Note 12) - - 1,030 1,030 - - 3,042 3,042 Details regarding fair value measurement at Levels 2 and 3 Financial instrument Valuation method for determining fair value Significant unobservable inputs Warrants Black - Scholes expected term 5.5 years expected volatility 81.66% annual risk free interest 1.94% dividend yield 0% Investment and Put option to Taoz Monte–Carlo Simulation Valuation at milestone (USD thousand) 12,000 – 17,000 Share Price (USD) 812 – 1,150 Probability of reaching milestone (%) 50% Risk free interest rate (%) 1.71% - 1.97% expected volatility 74.96% The annual Expected Volatility applied was based on the historical volatility of comparable companies.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequents Events [Abstract]
Subsequent Events	Note 21 – Subsequent Events In October 2017, the Company announced that it had contracted for the acquisition of an additional 27% stake in TyrNovo (the “Newly Acquired TyrNovo Shares”), from a group of unaffiliated minority shareholders of TyrNovo, who collectively held 4,024 ordinary shares, or approximately 27%, of TyrNovo. In exchange for these Newly Acquired TyrNovo Shares, the Company will issue to these unaffiliated minority shareholders of TyrNovo, in aggregate, 13,169,689 newly issued ordinary shares (equivalent to 658,484 American Depositary Shares or ADSs) of the Company, which represent approximately 6% of the Company’s issued and outstanding share capital . After the closing of this new share exchange transaction, which is pending receipt by the selling TyrNovo shareholders of a tax ruling from the Israeli Tax Authority or an exemption from withholding at source, and assuming no other issuances of equity by TyrNovo until such time Kitov will hold approximately 91.9% of TyrNovo’s issued and outstanding ordinary shares. The closing of this transaction is expected to take place by March 15, 2018. Approximately 3.9% of TyrNovo’s ordinary shares are owned by the founder and Chief Technology Officer of TyrNovo. An additional approximately 4.1% of TyrNovo’s ordinary shares are owned by Taoz - Company for Management and Holdings of Companies Ltd. (“Taoz”), a minority shareholder with whom the Company entered into a shareholders’ agreement in February 2017. See also Note 12. As part of the shareholders’ agreement entered into by the Company with Taoz, Taoz had the right to purchase TyrNovo shares from the Company under certain defined circumstances. This right expired on February 9, 2018.

Significant Accounting Polici27

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Significant Accounting Policies [Abstract]
Basis of consolidation	A. Basis of consolidation 1. Business combination The Group accounts for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Any goodwill that arises is tested annually for impairment. Any gain on a bargain purchase is recognized in profit or loss immediately. Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities. The consideration transferred does not include amounts related to the settlement of pre-existing relationships. Such amounts are generally recognized in profit or loss. Any contingent consideration is measured at fair value at the date of acquisition. If an obligation to pay contingent consideration that meets the definition of a financial instrument is classified as equity, then it is not re-measured and settlement is accounted for within equity. Otherwise, other contingent consideration is re-measured at fair value at each reporting date and subsequent changes in the fair value of the contingent consideration are recognized in profit or loss. If share-based payment awards (replacement awards) are required to be exchanged for awards held by the acquiree’s employees (acquiree’s awards), then all or a portion of the amount of the acquirer’s replacement awards is included in measuring the consideration transferred in the business combination. This determination is based on the market-based measure of the replacement awards compared with the market-based measure of the acquiree’s awards and the extend to which the replacement awards relate to the pre-combination service. 2. Subsidiary Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. 3. Non-controlling interests Non-controlling interests are measured initially at their proportionate share of the acquiree’s identifiable net assets at the date of acquisition. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.
Foreign currency transactions	B. Foreign currency transactions Transactions in foreign currency are translated to the functional currency of the Group at exchange rates as of the transaction dates. Monetary assets and liabilities denominated in foreign currency as of the reporting date are translated into the functional currency at the exchange rate as of the said date. Exchange rate differences with respect to monetary items are the differences between the amortized cost in the functional currency as of the start of the year, adjusted for the effective interest during the year, and the amortized cost in foreign currency, translated at the exchange rate as of the end of the year. Non-monetary items denominated in foreign currency and measured at historical cost, are translated using the exchange rate as of the transaction date. Exchange rate differences arising from translation into the functional currency are recognized on the statement of operations as financial expenses.
Derivative and Non-derivative financial instruments	C. Derivative and Non-derivative financial instruments 1. Non-Derivative financial instruments a. Non-derivative financial assets Non-derivative financial assets include: cash and cash equivalents, short term deposits and other receivables. Cash and cash equivalents include cash balances available for immediate use and call deposits. Cash equivalents include short-term highly liquid investments (with original maturities of three months or less) that are readily convertible into known amounts of cash and are exposed to insignificant risks of change in value. b. Non-derivative financial liabilities Non-derivative financial liabilities include: accounts payables and other accounts payable. Initial recognition of financial liabilities: The Group initially recognizes debt instruments issued as they are created. Other financial liabilities are initially recognized on the trade date on which the Group becomes party to contractual terms of the instrument. Financial liabilities are initially recognized at fair value less any attributable transaction costs. Subsequent to initial recognition, financial liabilities are measured at amortized cost using the effective interest method. Transaction costs directly attributable to an expected issuance of an instrument that will be classified as a financial liability are recognized as an asset as part of deferred expenses in the statement of financial position. These transaction costs are deducted from the financial liability upon their initial recognition, or are amortized as financing expenses in the statement of operations when the issuance is no longer expected to occur. De-recognition of financial liabilities: Financial liabilities are de-recognized upon expiration of the Group’s liability, as set forth in the agreement, or when discharged or cancelled. 2. Derivative financial liabilities The Group holds derivative financial instruments that do not serve hedging purposes, including separable embedded derivatives. Measurement of derivative financial instruments Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are accounted for as described below. The changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these derivatives is based on an evaluation prepared by external experts, and classified as level 3.
Intangible assets	D. Intangible assets 1. Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. The expenditure capitalized in respect of development activities includes the cost of materials, direct labor and overhead costs that are directly attributable to preparing the asset for its intended use, and capitalized borrowing costs. Other development expenditure is recognized in profit or loss as incurred. In subsequent periods, any capitalized development expenditure is measured at cost less accumulated amortization and accumulated impairment losses. As the Group has not met the criteria mentioned above, all development costs are currently recognized in profit and loss as expense. 2. Other intangible assets Other intangible assets, including in-process research and development in respect of the Company’s acquisition of TyrNovo (see also Note 4), which have infinite useful lives, are measured at cost less accumulated impairment losses. 3. Amortization Amortization is a systematic allocation of the amortizable amount of an intangible asset over its useful life. The amortizable amount is the cost of the asset less its residual value. Amortization is recognized in profit or loss on a straight-line basis, over the estimated useful lives of the intangible assets from the date they are available for use, since these methods most closely reflect the expected pattern of consumption of the future economic benefits embodied in each asset. Goodwill and intangible assets having an indefinite useful life are not systematically amortized but are tested for impairment at least once a year. Internally generated intangible assets are not systematically amortized as long as they are not available for use, i.e. they are not yet on site or in working condition for their intended use. Accordingly, these intangible assets, such as development costs, are tested for impairment at least once a year, until such date as they are available for use. Amortization methods, useful lives and residual values are reviewed at the end of each reporting year and adjusted if appropriate. The Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether events and circumstances continue to support the decision that the intangible asset has an indefinite useful life.
Loss per share	E. Loss per share The Group presents loss per share data for its ordinary share capital. Loss per share is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding during the period.
Share-based payment transactions	F. Share-based payment transactions The grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and non-market performance conditions at the vesting date.
Financing income and expense	G. Financing income and expense Finance income comprises changes in the fair value of the financial liability through profit and loss, and income from short term deposits. Finance expenses include loss from exchange rate differences. Interest expense is recognized, using the effective interest method. In the statements of cash flows, interest received and interest paid are presented as part of cash flows from financing activities.
Equity	H. Equity Incremental costs directly attributable to an expected issuance of an instrument that will be classified as equity are recognized as an asset in deferred expenses in the statement of financial position. The costs are deducted from the equity upon the initial recognition of the equity instruments, or are expensed as financing expenses in the statement of operations when the issuance is no longer expected to take place.
Issuance of units of securities	I. Issuance of units of securities The consideration received from the issuance of units of securities is attributed initially to financial liabilities that are measured each period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair value. The remaining amount is the value of the equity component. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described above.
Employee benefits	J. Employee benefits The Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance companies or with funds managed by a trustee, and they are classified as defined contribution plans and as defined benefit plans. A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Other long-term employee benefits The Group’s net obligation in respect of defined benefit plans is calculated separately for each plan by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets. The calculation of defined benefit obligations is performed annually by a qualified actuary using the projected unit credit method. When the calculation results in a potential asset for the Group, the recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. To calculate the present value of economic benefits, consideration is given to any applicable minimum funding requirements. Re-measurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in OCI. The Group determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss.
New standards and interpretations not yet adopted	K. New standards and interpretations not yet adopted IFRS 15, Revenue from contracts with customers IFRS 15 replaces the current guidance regarding recognition of revenues and presents a comprehensive framework for determining whether revenue should be recognized and when and at what amount. IFRS 15 is applicable for annual periods beginning on or after January 1, 2018 and earlier adoption is permitted. As the Group has not commenced serving activity in its opinion there would be no effect on the financial statements. IFRS 9 (2014), Financial Instruments IFRS 9 (2014) replaces the current guidance in IAS 9, Financial Instruments: Recognition and Measurement. IFRS 9 (2014) includes revised guidance of the classification and measurement of financial instruments, expected ‘credit loss’ model for calculating impairment for most financial assets, and new guidance and requirements with respect to hedge accounting. IFRS 9 (2014) is applicable for annual periods beginning on or after January 1, 2018 and earlier adoption is permitted. The Group has examined the effects of applying IFRS 9 (2014), and in its opinion the effect on the financial statements will be immaterial. IFRS 16, Leases IFRS 16 replaces IAS 17, Leases IFRS 16 is applicable for annual periods as of January 1, 2019, with the possibility of early adoption, so long as the Group has also early adopted IFRS 15, Revenue from Contracts with Customers The Group decided not to early adopt IFRS 16 and will examine its adoption’s effects in the future. IFRIC 22, Foreign Currency Transactions and Advance Consideration The interpretation provides that the transaction date for the purpose of determining the exchange rate for recording a foreign currency transaction that includes advanced consideration is the date of initial recognition of the non-monetary asset/liability from the prepayment. If there are multiple payments or receipts in advance, a transaction date is established for each payment or receipt. IFRIC 22 is applicable for annual periods beginning on or after January 1, 2018 and earlier adoption is permitted. The Group has examined the effects of applying IFRIC 22, and in its opinion there will be no effect on the financial statements.

Basis of Preparation of the F28

Basis of Preparation of the Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2017
Basis of Preparation of the Financial Statements [Abstract]
Schedule of changes in exchange rates	Representative exchange rate of USD (NIS/USD 1) Date of financial statements: December 31, 2017 3.467 December 31, 2016 3.845 December 31, 2015 3.902 Changes in exchange rates for the Year ended: % December 31, 2017 (9.8 ) December 31, 2016 (1.5 ) December 31, 2015 0.3

Acquisition of Subsidiary (Tabl

Acquisition of Subsidiary (Tables)	12 Months Ended
	Dec. 31, 2017
Acquisition of Subsidiary [Abstract]
Summary of acquisition date fair value of each major class of consideration	USD thousands Cash 2,000 Equity instruments issued (11,292,508 Ordinary Shares) (1) 1,800 Assignment of loan to the Company (101 ) Total consideration transferred 3,699 (1) Equity instruments issued The fair value of the Ordinary Shares issued was based on the listed share price of the Group at January 11, 2017 of approximately USD 0.16 per share (USD 3.14 per ADS).
Summary of recognized amounts of assets acquired and liabilities assumed at the date of acquisition	USD thousands Current assets 21 Fixed assets, net 3 Intangible assets (2) 6,172 Short-term credit from bank (16 ) Trade payables (123 ) Other payables (212 ) Long-term related parties (130 ) Total net identifiable assets 5,715 (2) In-process research and development Purchased in-process research and development expense represents the value assigned to research and development projects, which were commenced but not yet completed at the date of acquisition. Technological feasibility for these projects has not been established and they have no alternative future use in research and development activities or otherwise.

Subsidiaries (Tables)

Subsidiaries (Tables)	12 Months Ended
	Dec. 31, 2017
Subsidiaries [Abstract]
Schedule of condensed information regarding subsidiary directly held by company	Amounts provided by the Company to the subsidiary Incorporated and operates in Israel Group’s ownership equity Company’s direct ownership of equity Loans Guarantees Total investment in subsidiary USD thousands Kitov Pharmaceuticals Ltd. (1) Israel 100 % 100 % (19,481 ) - (19,748 ) TyrNovo Ltd. Israel 64.72 % 64.72 % (1,597 ) - 2,404 (1) With regards to its merger with the Company, see also Note 1.

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2017
Cash and Cash Equivalents [Abstract]
Schedule of cash and cash equivalents	As of December 31 2017 2016 USD thousands Balance in USD 3,322 4,980 Balance in other currencies *625 1,778 Total cash and cash equivalents 3,947 6,758 (*) including an amount of USD 50 thousand as guarantee for the Group’s leases. See also Note 13A1.

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Other Current Assets [Abstract]
Schedule of other current assets	As of December 31 2017 2016 USD thousands Government authorities 171 151 Prepaid expenses and other receivables * 377 90 Total other current assets 548 241 (*) Including an amount of USD 166 thousand, as of December 31, 2017, representing deposits entrusted to Israeli court on behalf of related parties pursuant to an indemnification obligation of the Company, in respect of an investigation of the Israeli Security Authority against the Company. See also Note 13B3.

Other Payables (Tables)

Other Payables (Tables)	12 Months Ended
	Dec. 31, 2017
Other Payables [Abstract]
Schedule of other payables	As of December 31 2017 2016 USD thousands Due to related parties 1,059 548 Due to GHP (note 4) 167 - Accrued expenses 326 76 Government authorities 107 - Payroll related payables 87 134 Deferred income (1) 95 - 1,841 758 (1) On March 2, 2017, the Group signed an agreement with a distributor granting exclusive right and license to manufacture, distribute and sell certain of the Groups products in South Korea, in accordance with the agreement between the parties.

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Schedule of company's share capital	As of December 31, 2017 As of December 31, 2016 Number of shares thousand Authorized Issued and paid-in Authorized Issued and paid-in Ordinary shares, no par value 5,000,000 224,443 5,000,000 153,237 Class A preferred shares, no par value 2,000 - 2,000 - Class B preferred shares, no par value 2,000 - 2,000 - Class C preferred shares, no par value 2,000 - 2,000 - Class D preferred shares, no par value 2,000 - 2,000 - Class E preferred shares, no par value 2,000 - 2,000 -
Schedule of changes in share capital during the year	For the year ended December 31 2017 2016 2015 Number of shares thousand Issued as at January 1 153,237 77,756 5,972 Issuance of ADSs 48,635 47,576 63,178 Issuance of shares *11,293 - 6,388 Share issuance deriving from a strategic cooperation agreement - 3,010 597 Share issuance due to meeting of milestone - - 1,379 Share based payments 11,278 669 - Exercise of warrants - 24,226 242 Issued as at December 31 224,443 153,237 77,756 (*) See Note 4.
Summarizes information relating to subsidiary that has material non-controlling interests	December 31, 2017 TyrNovo Ltd. Non-controlling interests percentage 35.28 % Non-current assets 3 Current assets 158 Current liabilities (2,676 ) Net assets (2,515 ) Net assets attributable to non-controlling interests (887 ) Loss 2,088 Loss allocated to non-controlling interests 736

Share-based Payment Arrangeme35

Share-based Payment Arrangements (Tables)	12 Months Ended
	Dec. 31, 2017
Share-based Payment Arrangements [Abstract]
Summary of number and weighted average exercise prices (in nis) of share options	Weighted average exercise price Number of options 2017 2016 2015 2017 2016 2015 Outstanding at January 1 0.83 0.81 0.78 10,394,915 3,510,729 3,872,359 Expired during the year 4 0.81 0.80 44,786 2,865,943 406,416 Granted during the year 0.33 0.79 4.00 9,690,299 9,750,129 44,786 Outstanding at December 31 0.36 0.83 0.81 20,040,428 10,394,915 3,510,729 Exercisable at December 31 0.32 0.96 0.83 14,177,578 2,269,808 3,285,729
Summary of number of RSUs	Number of RSUs 2017 Outstanding at January 1 - Granted during the year 13,345,205 Vested during the year (9,930,671 ) Outstanding at December 31 3,414,534
Summary of options to service providers were measured at the fair value of the service	2017 2016 Share Price - NIS 0.326-0.388 0.21-0.26 Option price - USD 0.164-0.191 1.07-1.42 Expected volatility (%) 80.65-80.91 - Expected duration (years) 6.77-6.97 4-8 Dividend yield (%) - - Risk free rate interest rate (%) 1.36-1.39 N/A
Summary of share based expenses	For the year ended December 31 2017 2016 2015 USD thousands Total share-based expense recognized 2,308 400 59

Transactions and Balances wit36

Transactions and Balances with Related Parties (Tables)	12 Months Ended
	Dec. 31, 2017
Transactions and Balances with Related Parties [Abstract]
Schedule of payments to key management	For the year ended December 31 2017 2016 2015 USD thousands Short - term employee benefits 2,522 1,336 1,207 Post-employment benefits 137 25 185 Share based payments 1,905 244 7 4,564 1,605 1,399

General and Administrative Ex37

General and Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
General and Administrative Expenses [Abstract]
Summary of general and administrative expenses	For the year ended December 31 2017 2016 2015 USD thousands Employee and officer compensation 1,984 1,131 515 Share-based payments (see also Note 10) 1,224 121 26 Legal fees in connection with ISA investigation and class action lawsuits (see also note 13B) 893 84 - Other professional consulting 1,306 1,059 728 Board member remuneration and insurance 552 155 67 Rent and office maintenance 196 94 95 Travel 131 99 13 Car expenses 64 42 27 Depreciation 4 2 1 Other 38 216 37 6,392 3,003 1,509

Finance Expense (Income) (Table

Finance Expense (Income) (Tables)	12 Months Ended
	Dec. 31, 2017
Finance Expense (Income) [Abstract]
Summary of net change in fair value of derivatives	For the year ended December 31 2017 2016 2015 USD thousands Net change in fair value of derivatives Expenses * 1,049 5,160 - Income - (141 ) (94 ) Net change in fair value of derivatives 1,049 5,019 (94 ) * This expense is related to the fair value adjustments of warrants. The warrants include an anti-dilution provision whereby the exercise price of the warrants are subject to “weighted average” ratchet anti-dilution provision, so that upon future issuance of the Company’s ADSs or an equivalent number of ordinary shares, subject to specified exceptions, at a price less than the exercise price then in effect, the exercise price will be reduced. The ratchet for the 2017 warrants expired on January 14, 2018, and the ratchet for the 2016 Series A warrants expired on November 25, 2016.
Summary of financing expenses (Income)	For the year ended December 31 2017 2016 2015 USD thousands Finance expense Fees and interest expense 26 6 3 Loss from exchange rate differences, net - 55 79 Credit allocation fee ** - - 141 Warrant issuance costs - - 4 26 61 227 ** In August 2015 the Company entered into loan agreements with several third parties (the “Lenders”) pursuant to which, they extended the Company loans of USD 430 thousand. The loans were repaid in November 2015 with an addition of credit allocation fees in the amount of $141 thousand. For the year ended December 31 2017 2016 2015 USD thousands Finance income Income from exchange rate differences, net (22 ) - - Interest income from short term deposits (106 ) (138 ) - (128 ) (138 ) -

Employee Benefits (Tables)

Employee Benefits (Tables)	12 Months Ended
	Dec. 31, 2017
Employee Benefits [Abstract]
Summary of post-employee benefits	December 31. 2017 2016 USD thousands USD thousands Short-term benefits 112 670 Post-employment benefits 492 256
Summary of defined contribution plan in respect of its employees	Year ended December 31 2017 2016 2015 USD thousands USD thousands USD thousands Amount recognized as expense in respect of defined contribution plan 52 39 25

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2017
Financial Instruments [Abstract]
Schedule of financial instruments measured at fair value	December 31, 2017 Level 1 Level 2 Level 3 Total USD thousands Financial liabilities Warrants (see Note 9(C)(1)) - - 2,012 2,012 Put option to Taoz (see Note 12) - - 1,030 1,030 - - 3,042 3,042
Schedule of fair value measurement	Financial instrument Valuation method for determining fair value Significant unobservable inputs Warrants Black - Scholes expected term 5.5 years expected volatility 81.66% annual risk free interest 1.94% dividend yield 0% Investment and Put option to Taoz Monte–Carlo Simulation Valuation at milestone (USD thousand) 12,000 – 17,000 Share Price (USD) 812 – 1,150 Probability of reaching milestone (%) 50% Risk free interest rate (%) 1.71% - 1.97% expected volatility 74.96%

General (Details)

General (Details) - USD ($) $ in Thousands	1 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Nov. 30, 2015	Dec. 31, 2017	Dec. 31, 2016
General [Abstract]
Accumulated deficit				$ (38,567)	$ (26,200)
Fund raised for current development plans	$ 23,600	$ 23,600	$ 23,600
Description of warrants to purchase ADS			Each ADS represents 20 ordinary shares with no par value. Each warrant enables the purchase of 1 ADS.

Basis of Preparation of the F42

Basis of Preparation of the Financial Statements (Details) - Bank of Israel [Member] - NIS	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Foreign Exchange Rates [Line Items]
Representative exchange rate of USD (NIS/USD 1)	3.467	3.845	3.902
Changes in exchange rates for the Year ended	(9.80%)	(1.50%)	0.30%

Other Receivables (Details)

Other Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Receivables [Abstract]
Government authorities	$ 180	$ 151
Prepaid expenses	410	90
Total receivables	$ 590	$ 241

Acquisition of Subsidiary (Deta

Acquisition of Subsidiary (Details) $ in Thousands	Jan. 13, 2017USD ($)
Summary of acquisition date fair value of each major class of consideration:
Cash	$ 2,000
Equity instruments issued (11,292,508 Ordinary Shares)	1,800
Assignment of loan to the Company	(101)
Total consideration transferred	$ 3,699

Acquisition of Subsidiary (De45

Acquisition of Subsidiary (Details 1) $ in Thousands	Jan. 13, 2017USD ($)
Summary of recognized amounts of assets acquired and liabilities assumed at the date of acquisition:
Current assets	$ 21
Fixed assets, net	3
Intangible assets	6,172
Short-term credit from bank	(16)
Trade payables	(123)
Other payables	(212)
Long-term related parties	(130)
Total net identifiable assets	$ 5,715

Acquisition of Subsidiary (De46

Acquisition of Subsidiary (Details Textual) - USD ($)	Jan. 13, 2017	Dec. 31, 2017	Oct. 31, 2017	Jan. 11, 2017	Aug. 31, 2015
Acquisition of Subsidiary (Textual)
Cash proceeds	$ 2,000,000
Ordinary shares issued	11,292,508
Loans					$ 430,000
Cash consideration paid	$ 167,157
Fair value of ordinary shares issued price per share				$ 0.16
ADS [Member]
Acquisition of Subsidiary (Textual)
Fair value of ordinary shares issued price per share				$ 3.14
TyrNovo [Member]
Acquisition of Subsidiary (Textual)
Cash proceeds	$ 2,000,000
Percentage of ordinary shares acquired	65.00%		27.00%
Ordinary shares issued	9,570		13,169,689
Loans	$ 101,157
Contributed losses		$ 2,088,000
TyrNovo [Member] | ADS [Member]
Acquisition of Subsidiary (Textual)
Ordinary shares issued			658,484
GHP [Member]
Acquisition of Subsidiary (Textual)
Ordinary shares issued	11,292,508

Subsidiaries (Details)

Subsidiaries (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Kitov Pharmaceuticals Ltd. [Member]
Disclosure of subsidiaries [line items]
Name of subsidiary	Kitov Pharmaceuticals Ltd.
Country of incorporation of subsidiary	Israel
Group's ownership equity	100.00%
Company's direct ownership of equity	100.00%
Amounts provided by the Company to the subsidiary Loan	$ (19,481)
Amounts provided by the Company to the subsidiary Guarantees
Total investment in subsidiary	$ (19,748)
TyrNovo Ltd [Member]
Disclosure of subsidiaries [line items]
Name of subsidiary	TyrNovo Ltd.
Country of incorporation of subsidiary	Israel
Group's ownership equity	64.72%
Company's direct ownership of equity	64.72%
Amounts provided by the Company to the subsidiary Loan	$ (1,597)
Amounts provided by the Company to the subsidiary Guarantees
Total investment in subsidiary	$ 2,404

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Disclosure Of Cash And Cash Equivalents [Line Items]
Total cash and cash equivalents	$ 3,947	$ 6,758	$ 10,558	$ 1,313
USD [Member]
Disclosure Of Cash And Cash Equivalents [Line Items]
Total cash and cash equivalents	3,322	4,980
Other curencies [Member]
Disclosure Of Cash And Cash Equivalents [Line Items]
Total cash and cash equivalents	$ 625	$ 1,778

Cash and Cash Equivalents (De49

Cash and Cash Equivalents (Details Textual) $ in Thousands	Dec. 31, 2017USD ($)
Cash and Cash Equivalents (Textual)
Guarantee for Group's leases	$ 50

Other Current Assets (Details)

Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Current Assets [Abstract]
Government authorities	$ 171	$ 151
Prepaid expenses and other receivables	377	90
Total other current assets	$ 548	$ 241

Other Current Assets (Details T

Other Current Assets (Details Textual) $ in Thousands	Dec. 31, 2017USD ($)
Other Current Assets (Textual)
Deposits	$ 166

Other Payables (Details)

Other Payables (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Payables [Abstract]
Due to related parties (note 10)	$ 1,059	$ 548
Due to GHP (note 4)	167
Accrued expenses	326	76
Government authorities	107
Payroll related payables	87	134
Deferred income	95
Other Payables Total	$ 1,841	$ 758

Equity (Details)

Equity (Details) - shares shares in Thousands	Dec. 31, 2017	Dec. 31, 2016
Ordinary shares [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	5,000,000	5,000,000
Number of shares, Issued and paid-in	224,443	153,237
Class A preferred shares [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	2,000	2,000
Number of shares, Issued and paid-in
Class B preferred shares [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	2,000	2,000
Number of shares, Issued and paid-in
Class C preferred shares [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	2,000	2,000
Number of shares, Issued and paid-in
Class D preferred share [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	2,000	2,000
Number of shares, Issued and paid-in
Class E preferred shares [Member]
Disclosure of classes of share capital [line items]
Number of shares, Authorized	2,000	2,000
Number of shares, Issued and paid-in

Equity (Details 1)

Equity (Details 1) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Equity [Abstract]
Issued as at January 1	153,237	77,756	5,972
Issuance of ADSs	48,635	47,576	63,178
Issuance of shares	11,293		6,388
Share issuance deriving from a strategic cooperation agreement		3,010	597
Share issuance due to meeting of milestone			1,379
Share based payments	11,278	669
Exercise of warrants		24,226	242
Issued as at December 31	224,443	153,237	77,756

Equity (Details 2)

Equity (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Noncontrolling Interests [Line Items]
Current assets	$ 7,983	$ 14,898
Current liabilities	4,068	1,273
Loss allocated to non-controlling interests	$ 736
Non-controlling interests [member] | TyrNovo Ltd. [Member]
Noncontrolling Interests [Line Items]
Non-controlling interests percentage	35.28%
Non-current assets	$ 3
Current assets	158
Current liabilities	(2,676)
Net assets	(2,515)
Net assets attributable to non-controlling interests	(887)
Loss	2,088
Loss allocated to non-controlling interests	$ 736

Equity (Details Textual)

Equity (Details Textual) - USD ($)	Oct. 30, 2017	Jul. 31, 2017	Jul. 31, 2016	May 31, 2016	Nov. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Feb. 09, 2017
Disclosure of classes of share capital [line items]
Placement agent fees and other offering related expenses						$ 1,306,000	$ 1,059,000	$ 728,000
Public offering price per unit									$ 476.48
Shares to service providers for services granted	1,347,340						669,100
Shares to service providers for services granted, value							$ 103,000
General and administrative expenses						$ 6,333,000	$ 3,003,000	$ 1,509,000
Ordinary share [Member]
Disclosure of classes of share capital [line items]
Shares to service providers for services granted	9,930,672					9,930,672
Dexcel Ltd. [Member]
Disclosure of classes of share capital [line items]
Shares to service providers for services granted				3,009,888
Shares to service providers for services granted, value				$ 500
Series A warrant [Member]
Disclosure of classes of share capital [line items]
Public offering issued by securities					3,158,900
Warrants to purchase shares of common stock			2,378,823
Shares to service providers for services granted							1,214,340
Proceeds from exercise of warrants							$ 302,000
Direct Offering [Member]
Disclosure of classes of share capital [line items]
Company funds raised		$ 3,500,000
Placement agent fees and other offering related expenses		$ 3,100,000
Public Offering [Member]
Disclosure of classes of share capital [line items]
Company funds raised			$ 12,000,000		$ 13,000,000
Placement agent fees and other offering related expenses			$ 10,000,000
Public offering price			$ 3.40
Exercise price					$ 4.956
Warrants to purchase shares of common stock					157,945
Deduction of underwrters commisions					$ 10,600,000
Company issued securities, description			(i) 2,378,823 Class A units - comprised of 2,378,823 ADSs and 2,378,823 Series A warrants to purchase 2,378,823 ADSs, and (ii) 1,150,589 Class B units - comprised of 1,150,589 prefunded Series B warrants to purchase 1,150,589 ADSs and 1,150,589 Series A warrants to purchase 1,150,589 ADSs		Company issued 3,158,900 ADSs and 3,158,900 Series A warrants to purchase 3,158,900 ADSs. Each ADS represents 20 ordinary shares with no par value. Each warrant enables the purchase of 1 ADS. The public offering was completed at a price of USD 4.13 for a unit of 1 ADS and 1 warrant. Each warrant is exercisable for a period of 5 years for an initial exercise price of USD 4.13, which has since been adjusted to USD 3.78. In addition, the Company granted the underwriters the right to sell within 45 days up to 473,835 ADSs and/or 473,835 Series A warrants at the same terms as the public offering (of which the underwriters exercised the right to sell 220,074 warrants)
ADS [Member]
Disclosure of classes of share capital [line items]
Concurrent private placement issued		2,431,746
Warrant exercise price		$ 1.50	$ 4.08
Warrants to purchase shares of common stock		1,215,873	141,176
Shares to service providers for services granted	67,367
Shares to service providers for services granted, value	$ 96,000
General and administrative expenses	83,000
Deferred prepaid expenses	$ 13,000
Non-listed warrants		1,215,873
Issue of equity						$ 2,174,000
ADS [Member] | Series A warrant [Member]
Disclosure of classes of share capital [line items]
Warrant exercise price			$ 3.78
Warrants to purchase shares of common stock			2,378,823
ADS [Member] | Series B warrant [Member]
Disclosure of classes of share capital [line items]
Warrant exercise price			$ 0.01

Share-based Payment Arrangeme57

Share-based Payment Arrangements (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Weighted average exercise price (in NIS)
Outstanding at January 1	$ 0.83	$ 0.81	$ 0.78
Expired during the year	4	0.81	0.8
Granted during the year	0.33	0.79	4
Outstanding at December 31	0.36	0.83	0.81
Exercisable at December 31	$ 0.32	$ 0.96	$ 0.83
Number of options
Outstanding at January 1	10,394,915	3,510,729	3,872,359
Expired during the year	44,786	2,865,943	406,416
Granted during the year	9,690,299	9,750,129	44,786
Outstanding at December 31	20,040,428	10,394,915	3,510,729
Exercisable at December 31	14,177,578	2,269,808	3,285,729

Share-based Payment Arrangeme58

Share-based Payment Arrangements (Details 1)	12 Months Ended
	Dec. 31, 2017shares
Number of RSUs
Outstanding at January 1
Granted during the year	13,345,205
Vested during the year	(9,930,671)
Outstanding at December 31	3,414,534

Share-based Payment Arrangeme59

Share-based Payment Arrangements (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Disclosure of range of exercise prices of outstanding share options [line items]
Dividend yield (%)
Minimum [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Share Price - NIS	$ 0.326	$ 0.21
Option price - USD	$ 0.164	$ 1.07
Expected volatility (%)	80.65%
Expected duration (years)	6 years 9 months 7 days	4 years
Risk free rate interest rate (%)	1.36%
Maximum [member]
Disclosure of range of exercise prices of outstanding share options [line items]
Share Price - NIS	$ 0.388	$ 0.26
Option price - USD	$ 0.191	$ 1.42
Expected volatility (%)	80.91%
Expected duration (years)	6 years 11 months 19 days	8 years
Risk free rate interest rate (%)	1.39%

Share-based Payment Arrangeme60

Share-based Payment Arrangements (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Payment Arrangements [Abstract]
Total share-based expense recognized	$ 2,308	$ 400	$ 59

Share-based Payment Arrangeme61

Share-based Payment Arrangements (Details Textual) $ / shares in Units, $ in Thousands

Aug. 15, 2017USD ($)$ / sharesshares

Aug. 15, 2017₪ / sharesshares

Aug. 01, 2017USD ($)shares

Aug. 01, 2017₪ / sharesshares

Aug. 31, 2017

Jun. 30, 2017shares

Jun. 30, 2016USD ($)$ / sharesshares

Jun. 30, 2016₪ / shares

May 31, 2016shares

May 22, 2016

Nov. 25, 2015

Feb. 28, 2015USD ($)$ / sharesshares

Dec. 31, 2017USD ($)shares

Dec. 31, 2017₪ / sharesshares

Dec. 31, 2016₪ / sharesshares

Jan. 03, 2017shares

Dec. 31, 2015shares

Dec. 31, 2014shares

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of shares approved

224,443,000

224,443,000

153,237,000

153,237,000

77,756,000

5,972,000

Vesting period

3 years

Exercise period

7 years

Fair value expense | $

$ 2,196

Fair value of options and grants measured | $

$ 2,071

Additional ordinary shares

38,000,000

Top of range [member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Weighted average exercise price | ₪ / shares

₪ 1.20

₪ 4

Weighted average remaining contractual life

7 years 8 months 12 days

Bottom of range [member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Weighted average exercise price | ₪ / shares

₪ 0.33

₪ 0.79

Weighted average remaining contractual life

7 years 2 months 12 days

May 22, 2016 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Exercise period

7 years

RSUs [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Key management personnel | $

$ 1,905

Fully vested grant

558,000

Fair value of options and grants measured | $

$ 76

RSUs [Member] | November 25, 2015 [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Exercise period

7 years

Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant

160,000

Fair value of options and grants measured | $

$ 15

Board of Directors [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Options exercise price | ₪ / shares

₪ 0.3297

Fair value of options and grants measured | $

$ 680

Number of additional options granted

2,468,759

Board of Directors [Member] | RSUs [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of shares approved

348,000

348,000

12,161,000

12,161,000

Additional number of shares issued

836,000

836,000

Board of Directors [Member] | Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of shares approved

580,000

580,000

8,790,000

8,790,000

Additional number of shares issued

320,000

320,000

Directors [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of grant option shares

5,957,485

5,957,485

Term of vesting share options

8 years

8 years

Two Consultants [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of options exercisable into shares

44,786

Description of options exercise term

24 months

Options exercise price | $ / shares

$ 4

Fair value of options and grants measured | $

$ 31

Number of grant option shares

44,786

Chairman of Board of Directors [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Options exercise price | (per share)

$ 0.7884

$ 0.205

₪ 0.7884

Number of grant option shares

7,281,370

7,281,370

Term of vesting share options

3 years

Service Provider [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Exercise period

7 years

Options exercise price | ₪ / shares

₪ 0.3297

Number of grant option shares

7,281,370

7,281,370

Service Provider [Member] | RSUs [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant

174,000

Fair value of options and grants measured | $

$ 32

Service Provider [Member] | Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant

580,000

Fair value of options and grants measured | $

$ 31

Directors and Officers [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Vesting period

3 years

Exercise period

7 years

Directors and Officers [Member] | RSUs [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant

438,000

Fair value of options and grants measured | $

$ 1,326

Directors and Officers [Member] | Options [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Fully vested grant

396,000

Fair value of options and grants measured | $

$ 592

Chief Executives Officer [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of grant option shares

7,281,370

7,281,370

Chief Financials Officer [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of grant option shares

7,281,370

7,281,370

Senior Employees [Member]

Disclosure of terms and conditions of share-based payment arrangement [line items]

Number of grant option shares

7,281,370

7,281,370

Transactions and Balances wit62

Transactions and Balances with Related Parties (Details) - Payments to Key Management [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Short - term employee benefits	$ 2,522	$ 1,336	$ 1,207
Post-employment benefits	137	25	185
Share based payments	1,905	244	7
Total	$ 4,564	$ 1,605	$ 1,399

Settlement with a Minority Sh63

Settlement with a Minority Shareholder of TyrNovo (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Feb. 09, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Settlement With A Minority Shareholder Of Tyrnovo [Abstract]
Name of acquiree	TyrNovo
Description of acquiree	A shareholder owning approximately 4% of TyrNovo, entered into a settlement arrangement in response to a motion filed by Taoz on January 19, 2017.
Measurement of issued and outstanding share capital, description	Taoz is entitled to be issued an additional 77 ordinary shares of TyrNovo, representing 0.5% of the issued and outstanding share capital of TyrNovo immediately following this issuance. The shares were issued in February 2017 and were measured at a fair value of USD 29 thousand.
Description of measurement basis for non-controlling interest in acquiree recognised at acquisition date	Taoz has the right during a defined period to invest an additional USD 1,750,000 (the "Deferred Investment") by way of convertible loans, with conversion terms defined under various circumstances, including the possibility of conversion at a price per share reflecting a 30% discount off the price per share paid in a subsequent financing round, and the possibility of conversion at a price per TyrNovo share reflecting a TyrNovo company valuation of USD 13,500,000.
Provided to Taoz a put option to sell, description	The Company provided to Taoz a put option to sell to the Company up to 50% of the TyrNovo shares issued to Taoz, exercisable during a period of 90 days from the publication by TyrNovo of the results of Phase I clinical trials, for a price per TyrNovo share equal to US$1,600, either in ordinary shares of the Company or, at the Company' sole discretion, in cash; upon the expiration of the 90 day exercise period, the put option, if not exercised by Taoz, shall expire and no longer be valid.
Rights granted, share options granted	$ 1,000	$ 1,030
other expenses		29
Finance expense	$ 30	$ 26	$ 61	$ 227
Price per share	$ 476.48

Commitments and Contingent Li64

Commitments and Contingent Liabilities (Details) ₪ in Thousands, $ in Thousands

Nov. 08, 2016

Mar. 20, 2017

Feb. 28, 2017USD ($)

Feb. 28, 2017ILS (₪)

Feb. 10, 2017

Feb. 07, 2017

Dec. 31, 2017USD ($)

Dec. 31, 2017ILS (₪)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Dec. 31, 2015ILS (₪)

Dec. 31, 2017ILS (₪)

Commitments and Contingent Liabilities (Textual)

Bonus amount

$ 1,056

$ 848

Issuance costs of the ADSs

363

Liability due to grants

$ 492

$ 256

Motion total amount

$ 4,300

₪ 16,400

Description, of lawsuit filing

The Company delivered its response to the court in accordance with applicable law. A preliminary hearing held by the court on September 12, 2016 and subsequently the court set a schedule for the submission by the petitioners of a motion for discovery, and any responses to such motion.

The Company delivered its response to the court in accordance with applicable law. A preliminary hearing held by the court on September 12, 2016 and subsequently the court set a schedule for the submission by the petitioners of a motion for discovery, and any responses to such motion.

Loss contingency actions taken by court arbitrator or mediator

The Motion to be excluded from the purported class and claiming to have independent causes of action and claims of approximately NIS 1 million.

Gains on litigation settlements

$ 8,000

₪ 29,000

Debt instrument offering date

Nov. 20, 2015

Nov. 20, 2015

Nov. 20, 2015

Bottom of range [member]

Commitments and Contingent Liabilities (Textual)

Annual interest rate of revenues

3.00%

3.00%

Top of range [member]

Commitments and Contingent Liabilities (Textual)

Annual interest rate of revenues

6.00%

6.00%

Office premises through to the end of 2020 and for car leases through mid - 2021 [Member]

Commitments and Contingent Liabilities (Textual)

Annual commitment under lease agreements

$ 203

₪ 702

TyrNovo [Member] | Israel Innovation Authority [Member]

Commitments and Contingent Liabilities (Textual)

Aggregate amount of grants received

1,600

₪ 5,500

Maximum royalty payable excluding interest amount

$ 1,600

₪ 5,500

Yissum [Member]

Commitments and Contingent Liabilities (Textual)

Description of license agreement

In consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license: (i) Royalties at a rate of three percent (3%) of net sales. (ii) Sublicense fees at a rate of twelve percent (12%) of sublicense consideration. In addition, Yissum is entitled to receive an Exit Fee of 12% of the transaction proceeds in the event of certain pre - defined transactions set forth in the License Agreement.

In consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license: (i) Royalties at a rate of three percent (3%) of net sales. (ii) Sublicense fees at a rate of twelve percent (12%) of sublicense consideration. In addition, Yissum is entitled to receive an Exit Fee of 12% of the transaction proceeds in the event of certain pre - defined transactions set forth in the License Agreement.

General and Administrative Ex65

General and Administrative Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
General and Administrative Expenses [Abstract]
Employee and officer compensation	$ 1,984	$ 1,131	$ 515
Share-based payments (see also Note 10)	1,224	121	26
Legal fees in connection with ISA investigation and class action lawsuits (see also note 13B)	893	84
Other professional consulting	1,306	1,059	728
Board member remuneration and insurance	552	155	67
Rent and office maintenance	196	94	95
Travel	131	99	13
Car expenses	64	42	27
Depreciation	4	2	1
Other	38	216	37
Total	$ 6,392	$ 3,003	$ 1,509

Other Expenses (Details)

Other Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Other Expenses (Textual)
Other expenses	$ 1,029

Finance Expense (Income) (Detai

Finance Expense (Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net change in fair value of derivatives
Expenses	$ 1,049	$ 5,160
Income		(141)	(94)
Net change in fair value of derivatives	$ 1,049	$ 5,019	$ (94)

Finance Expense (Income) (Det68

Finance Expense (Income) (Details 1) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Feb. 09, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Finance expense
Fees and interest expense		$ 26	$ 6	$ 3
Loss from exchange rate differences, net			55	79
Credit allocation fee				141
Warrant issuance costs				4
Finance expense	$ 30	26	61	227
Finance income
Income from exchange rate differences, net		(22)
Interest income from short term deposits		(106)	(138)
Finance income		$ (128)	$ (138)	$ 0

Finance Expense (Income) (Det69

Finance Expense (Income) (Details Textual) - USD ($) $ in Thousands	1 Months Ended
	Nov. 30, 2015	Aug. 31, 2015
Finance Expense (Income) (Textual)
Amount of loan payable		$ 430
Credit allocation fees	$ 141

Taxes on Income (Details)

Taxes on Income (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Taxes on Income (Textual)
Unrecognized deferred taxes for research and development expenses		$ 28.2	$ 13.2	$ 9
Corporate Tax Rate [Member]
Taxes on Income (Textual)
Corporate tax rate		24.00%
Changes in tax rates or tax laws enacted or announced [member]
Taxes on Income (Textual)
Corporate tax rate	23.00%

Employee Benefits (Details)

Employee Benefits (Details) - Post-employment benefits [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]
Short-term benefits	$ 112	$ 670
Post-employment benefits	$ 492	$ 256

Employee Benefits (Details 1)

Employee Benefits (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Employee Benefits [Abstract]
Amount recognized as general and administrative expense in respect of defined contribution plan	$ 52	$ 39	$ 25

Financial Instruments (Details)

Financial Instruments (Details) $ in Thousands	Dec. 31, 2017USD ($)
Disclosure of fair value measurement of equity [line items]
Warrants (see Note 9(C)(1))	$ 2,012
Put option to Taoz (see Note 12)	1,030
Financial liabilities	3,042
Level 1 [member]
Disclosure of fair value measurement of equity [line items]
Warrants (see Note 9(C)(1))
Put option to Taoz (see Note 12)
Financial liabilities
Level 2 [member]
Disclosure of fair value measurement of equity [line items]
Warrants (see Note 9(C)(1))
Put option to Taoz (see Note 12)
Financial liabilities
Level 3 [member]
Disclosure of fair value measurement of equity [line items]
Warrants (see Note 9(C)(1))	2,012
Put option to Taoz (see Note 12)	1,030
Financial liabilities	$ 3,042

Financial Instruments (Details

Financial Instruments (Details 1)	12 Months Ended
	Dec. 31, 2017USD ($)
Warrants [Member] | Black - Scholes [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
expected term	5 years 6 months
expected volatility	81.66%
annual risk free interest	1.94%
dividend yield	0.00%
Investment and Put option to Taoz [Member] | Monte - Carlo Simulation [Member]
Disclosure of continuing involvement in derecognised financial assets [line items]
expected volatility	74.96%
Probability of reaching milestone	50.00%
Investment and Put option to Taoz [Member] | Monte - Carlo Simulation [Member] | Top of range [member]
Disclosure of continuing involvement in derecognised financial assets [line items]
annual risk free interest	1.97%
Valuation at milestone	$ 17,000,000
Share Price	$ 1,150
Investment and Put option to Taoz [Member] | Monte - Carlo Simulation [Member] | Bottom of range [member]
Disclosure of continuing involvement in derecognised financial assets [line items]
annual risk free interest	1.71%
Valuation at milestone	$ 12,000,000
Share Price	$ 812

Financial Instruments (Detail75

Financial Instruments (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Financial Instruments (Textual)
Cash and cash equivalents and short term deposits	$ 7,435	$ 14,657
Bottom of range [member]
Financial Instruments (Textual)
Short term deposits fixed interest rate	0.14%
Top of range [member]
Financial Instruments (Textual)
Short term deposits fixed interest rate	1.60%

Subsequent Events (Details)

Subsequent Events (Details) - shares	1 Months Ended
	Oct. 31, 2017	Feb. 09, 2017	Jan. 13, 2017
Subsequents Event (Textual)
Ordinary shares issued			11,292,508
Owned shares, description		A shareholder owning approximately 4% of TyrNovo, entered into a settlement arrangement in response to a motion filed by Taoz on January 19, 2017.
TyrNovo [Member]
Subsequents Event (Textual)
Percentage of ordinary shares acquired	27.00%		65.00%
Ordinary shares	4,024
Issued and outstanding share capital percentage	6.00%
Ordinary shares issued	13,169,689		9,570
Owned shares, description	Approximately 3.9% of TyrNovo's ordinary shares are owned by the founder and Chief Technology Officer of TyrNovo. An additional approximately 4.1% of TyrNovo's ordinary shares are owned by Taoz - Company for Management and Holdings of Companies Ltd.
TyrNovo [Member] | ADS [Member]
Subsequents Event (Textual)
Ordinary shares issued	658,484
Kitov [Member]
Subsequents Event (Textual)
Issued and outstanding share capital percentage	91.90%
Taoz [Member]
Subsequents Event (Textual)
Owned shares, description	As part of the shareholders' agreement entered into by the Company with Taoz, Taoz had the right to purchase TyrNovo shares from the Company under certain defined circumstances. This right expired on February 9, 2018.